LONDON, March 24, 2022 /PRNewswire/ PharmaVentures is pleased to announce that it acted as transaction advisor to Lausanne University Hospital (CHUV) and EPFL in Switzerland on their commercial
Initial pipeline comprised of two monoclonal antibodies that show broad and significant neutralization of emerging SARS-CoV-2 variants; data posted on BioRXiv.